🚨 EMERGENCY POD: Ep 27 - Hims Inks Deal with Novo Nordisk To Sell Wegovy

In Episode 27 of Hims House, Jonathan Stern, Patrick Lester, and Louis Stevens discuss the blockbuster news of Hims partnering with Novo Nordisk to sell branded GLP-1 medication Wegovy for $599 a month. They delve into the deal terms, initial market reaction, and the potential long-term impacts on Hims as the direct-to-consumer telehealth leader. The conversation also touches on the possibility of future partnerships, notably with Eli Lilly, and how Hims' business model and profit margins might evolve.

00:00 Introduction

01:46 Patrick's Perspective on the Deal

08:09 Louis' Return and Reflections

09:58 Comparing Hims to Netflix and Long-term Prospects

15:46 Impact on Bear Thesis and Revenue Projections

21:12 Understanding Hims as an AI-Orchestrated General Physician

27:01 Wall Street's Obsession with GLP-1s

31:30 Margin Impact of the Novo Deal

40:01 Future Partnerships and 2025 Outlook

Disclaimer: This podcast is for informational and entertainment purposes only. Nothing discussed should be considered financial, investment, or legal advice. Always consult with a qualified professional before making financial decisions

Get full access to Hims House at himshouse.substack.com/subscribe